TR200101482T2 - WT1'e özgü imünoterapi için bileşimler - Google Patents

WT1'e özgü imünoterapi için bileşimler

Info

Publication number
TR200101482T2
TR200101482T2 TR2001/01482T TR200101482T TR200101482T2 TR 200101482 T2 TR200101482 T2 TR 200101482T2 TR 2001/01482 T TR2001/01482 T TR 2001/01482T TR 200101482 T TR200101482 T TR 200101482T TR 200101482 T2 TR200101482 T2 TR 200101482T2
Authority
TR
Turkey
Prior art keywords
compositions
polypeptide
specific immunotherapy
treatment
cell
Prior art date
Application number
TR2001/01482T
Other languages
English (en)
Inventor
Gaiger Alexander
Cheever Martin
Original Assignee
Corixa Corporation
Gaiger Alexander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corporation, Gaiger Alexander filed Critical Corixa Corporation
Publication of TR200101482T2 publication Critical patent/TR200101482T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Lösemi ve kanser gibi habis hastaliklarin tedavisi için bilesimler ve yöntemler tarif edilmektedir. Bilesimler bir WT1 polinükleotidi, bir WT1 polipeptidi, bir WT1 polipeptidi olusturan bir antijen olusturucu hücre, bir WT1 polipeptidine özel olarak baglanan bir antikor veya bir WT1 polipeptidi ile özel olarak tepkimeye girebilen bir T hücresinden bir veya daha fazlasini içerir. Bu tip bilesimler örnegin metastatik hastaliklarin önlenmesinde ve tedavi edilmesinde kullanilabilir.
TR2001/01482T 1998-09-30 1999-09-30 WT1'e özgü imünoterapi için bileşimler TR200101482T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
TR200101482T2 true TR200101482T2 (tr) 2002-01-21

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01482T TR200101482T2 (tr) 1998-09-30 1999-09-30 WT1'e özgü imünoterapi için bileşimler

Country Status (25)

Country Link
EP (1) EP1117687B1 (tr)
JP (3) JP4243792B2 (tr)
KR (1) KR100752065B1 (tr)
CN (1) CN100486995C (tr)
AR (1) AR021849A1 (tr)
AT (1) ATE399179T1 (tr)
AU (1) AU6407899A (tr)
BR (1) BR9914116A (tr)
CA (1) CA2349442C (tr)
CZ (1) CZ20011144A3 (tr)
DE (1) DE69938970D1 (tr)
ES (1) ES2310052T3 (tr)
HK (1) HK1039782B (tr)
HU (1) HUP0103598A3 (tr)
IL (2) IL142216A0 (tr)
MX (1) MXPA01003344A (tr)
MY (1) MY139226A (tr)
NO (1) NO325839B1 (tr)
NZ (1) NZ510600A (tr)
PL (1) PL201881B1 (tr)
RU (1) RU2237674C2 (tr)
SA (1) SA00200872B1 (tr)
TR (1) TR200101482T2 (tr)
TW (1) TWI285648B (tr)
WO (1) WO2000018795A2 (tr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
EP1261711A2 (en) * 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) * 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
CA2451846A1 (en) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
DE60329201D1 (de) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
KR20120054644A (ko) 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP2343083B1 (en) * 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (da) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
JP4394724B2 (ja) 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
CA2886551A1 (en) 2006-02-22 2007-08-30 Haruo Sugiyama Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
CN102850434B (zh) * 2006-10-17 2016-04-13 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
AU2007340679B2 (en) * 2006-12-28 2013-09-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
PT2119778E (pt) 2007-02-27 2016-02-15 Int Inst Cancer Immunology Inc Método para ativação de célula t auxiliar e composição para utilização no método
EP2444410A3 (en) * 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
US20100255020A1 (en) * 2007-11-20 2010-10-07 Nec Corporation Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
CA2881594C (en) * 2007-12-05 2016-04-12 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2432893B1 (en) * 2009-05-19 2019-05-01 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
WO2012135854A2 (en) 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides
CN105968191A (zh) 2011-06-28 2016-09-28 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
CN111781359A (zh) * 2013-05-13 2020-10-16 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3231438B1 (en) 2014-12-11 2020-06-17 International Institute of Cancer Immunology, Inc. Wt1 immunotherapy for intraocular angiogenic disease
EP3347028A1 (en) * 2015-09-10 2018-07-18 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy
CN116327903A (zh) * 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
CA3059644A1 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
MX2022013208A (es) * 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer
KR20230044133A (ko) * 2021-09-24 2023-04-03 주식회사 차백신연구소 종양 연관 항원으로부터 유래된 펩타이드 및 리포펩타이드와 면역활성물질로 구성되는 아쥬번트를 포함하는 항암 백신 조성물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033127T2 (de) * 1989-11-13 1999-10-14 Massachusetts Inst Technology Lokalisation und charakterisierung des wilms-tumor-gens
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Also Published As

Publication number Publication date
WO2000018795A2 (en) 2000-04-06
CN1336935A (zh) 2002-02-20
MXPA01003344A (es) 2004-04-21
DE69938970D1 (de) 2008-08-07
NO20011613L (no) 2001-05-29
CA2349442C (en) 2012-12-04
HUP0103598A2 (hu) 2002-01-28
PL201881B1 (pl) 2009-05-29
EP1117687B1 (en) 2008-06-25
JP4235984B2 (ja) 2009-03-11
NO325839B1 (no) 2008-07-28
JP4243792B2 (ja) 2009-03-25
NZ510600A (en) 2003-12-19
KR100752065B1 (ko) 2007-08-28
JP2008069172A (ja) 2008-03-27
IL142216A (en) 2009-06-15
JP2002525099A (ja) 2002-08-13
JP2007001984A (ja) 2007-01-11
AU6407899A (en) 2000-04-17
CA2349442A1 (en) 2000-04-06
ES2310052T3 (es) 2008-12-16
HK1039782B (zh) 2008-11-14
EP1117687A2 (en) 2001-07-25
TW200606176A (en) 2006-02-16
IL142216A0 (en) 2002-03-10
TWI285648B (en) 2007-08-21
ATE399179T1 (de) 2008-07-15
CN100486995C (zh) 2009-05-13
MY139226A (en) 2009-08-28
WO2000018795A9 (en) 2000-08-31
PL348595A1 (en) 2002-06-03
BR9914116A (pt) 2002-01-15
NO20011613D0 (no) 2001-03-29
RU2237674C2 (ru) 2004-10-10
HK1039782A1 (en) 2002-05-10
KR20010085861A (ko) 2001-09-07
AR021849A1 (es) 2002-08-07
HUP0103598A3 (en) 2005-11-28
WO2000018795A3 (en) 2000-10-26
CZ20011144A3 (cs) 2002-06-12
SA00200872B1 (ar) 2007-01-30

Similar Documents

Publication Publication Date Title
TR200101482T2 (tr) WT1'e özgü imünoterapi için bileşimler
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
TR200200937T2 (tr) Yumurtalık kanseri tedavisi için bileşimler.
HUP0102535A2 (hu) Új CD 19xCD3 specifikus polipeptidek és alkalmazásuk
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
PT724456E (pt) Anticorpos contra cd4
ATE335814T1 (de) Modifizierte arginindeaminase
DK0556310T3 (da) Quinazolinderivater til forhøjelse af antitumoraktivitet
TR200000115T2 (tr) Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler.
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
GR3026219T3 (en) Mouse monoclonal antibodies
NO963918L (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
TR200100462T2 (tr) Muskarinik agonistleri ve antagonistleri
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
DE69021742T2 (de) Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck.
TR200002269T2 (tr) Katı yakıt katkıları.
ATE285247T1 (de) Krebstherapie mit lymphotoxin
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
TR200101141T2 (tr) Antitümör etkiyi haiz antijenik proteini şifreleyen bir DNA'ya mahsus parçalar ihtiva eden farmasötik bileşim